The zeal for antibody-drug conjugates (ADCs), a prominent focus for dealmaking in 2023, shows no signs of waning, as Johnson & Johnson greeted attendees of the J.P. Morgan Healthcare Conference (JPM) with news of its $2 billion buyout of Ambrx Biopharma Inc., picking up rights to an ADC platform along with a promising candidate targeting advanced prostate cancer. Under the terms, J&J agreed to acquire all outstanding shares of San Diego-based Ambrx for $28 apiece, marketing a 105% premium to the firm’s Jan. 5 closing price. Unsurprisingly, Ambrx’s stock (NASDAQ:AMAM) gained 101.5% to close Jan. 8 at $27.47.
Hinova Pharmaceuticals Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to an estrogen receptor (ER)-targeting moiety through a linker.
Researchers from China Pharmaceutical University have reported the discovery and preclinical evaluation of novel bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer.
Sana Biotechnology Inc. has obtained FDA clearance of its IND application to conduct a study of SC-262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed chimeric antigen receptor (CAR) T therapy.
Researchers from Third Military Medical University of the Chinese PLA have published data from a study that aimed to investigate the biological functions and molecular mechanisms of tandem C2 domains, nuclear (TC2N) in the development and progression of breast cancer.
It is largely known that the expression of programmed cell death 1 ligand 1 (PD-L1) contributes to immune evasion by cancer cells, thus avoiding the cytotoxic effect exerted by T cells. Therefore, it is important to understand the mechanisms regulating PD-L1 levels.
Researchers at Monash University in Melbourne have discovered that transcription factors Ikaros and Aiolos work by binding to AP-1 transcriptional complexes and driving their transcription, which regulates thousands of genes in the human body.
Allogene Therapeutics Inc.’s decision to preferentially pursue first-line treatment of large B-cell lymphoma (LBCL) with CAR T cemacabtagene ansegedleucel (cema-cel, previously known as ALLO-501A) met mixed reviews on Wall Street.
RSS
